
Conference Coverage
about 23 hours ago
Managing Survodutide GI Adverse Effects: The Pharmacist's Roleabout 24 hours ago
Enlicitide in Primary Prevention: What PREVENT Data ShowLatest News

A Quick-Reference Guide for Multidisciplinary Stroke Prevention Rounds

Expanding Career Pathways in Pharmacy Education

Pharmacist-Led Initiative Enrolling Medicare-Eligible Patients in State Pharmaceutical Assistance Programs

FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC

Adrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C

Shorts










Continuing Education
All News

A new US DOL rule will require PBMs to disclose their compensation to large self-insured employer plans starting in 2027.

Salia Farrokh describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.

FDA Approves Secukinumab as First IL-17 Biologic for Polymyalgia Rheumatica
The FDA approved secukinumab for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering, supported by improved sustained remission and reduced steroid exposure in REPLENISH.

Preserving patient access requires attention to the people, workflows, and financial structures behind the pharmacy counter, not just the number of open pharmacy locations.

The breakthrough is not only in cell and gene therapies but also in whether health care can translate them into practice.

A clear and workable medication plan is an essential part of the transition home.

The FDA's decision comes weeks ahead of giredestrant's scheduled approval date.

Adults with AChR antibody–positive generalized myasthenia gravis now have a C5 inhibitor they can inject themselves at home once a week.

Semaglutide-Associated Sensory Skin Disturbance in Patients Without Diabetes Treated for Weight Loss
Peer Reviewed
This case series describes 2 instances of cutaneous sensory disturbance during semaglutide therapy in patients without diabetes and discusses possible mechanisms as hypotheses requiring further investigation.

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

The pertuzumab biosimilar is set to be commercially available in the third quarter of 2028.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.

An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.

A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.

How should a factor XIa inhibitor be incorporated into secondary stroke prevention?

Inconsistent state immunization laws complicate pharmacy operations and limit patient access.

Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.



































